Beyond The Numbers: 11 Analysts Discuss Biomarin Pharmaceutical Stock
Portfolio Pulse from Benzinga Insights
Eleven analysts have provided ratings on BioMarin Pharmaceutical (NASDAQ:BMRN) over the past three months, with a mix of bullish and somewhat bullish sentiments. The average 12-month price target has increased to $107.0, indicating a positive outlook. BioMarin's financials show strong revenue growth and net margin, but challenges in ROE. The company's debt management is favorable.
August 20, 2024 | 6:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BioMarin Pharmaceutical has received mixed but generally positive analyst ratings, with an increased average price target of $107.0. The company's financials show strong revenue growth and net margin, but challenges in ROE. Favorable debt management is noted.
The increase in the average price target and the generally positive sentiment from analysts suggest a likely positive short-term impact on BioMarin's stock price. The company's strong revenue growth and net margin further support this outlook, despite challenges in ROE.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100